Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Bipolar Disord. 2010 Dec;12(8):825–833. doi: 10.1111/j.1399-5618.2010.00884.x

Table 1.

Analyses of the population-averaged generalized estimating equations in all metabolites of interest

Treatment-by-visit interaction
Metabolites Coefa z p-value 95% CI
PME 0.841 5.03 < 0.001b 0.52–1.17
 PEtn 0.580 4.95 < 0.001b 0.35–0.81
 PCho 0.254 2.17  0.030b 0.02–0.48
PDE 0.005 0.03 0.979 −0.37–0.38
 GPEtn 0.065 0.58 0.565 −0.16–0.29
 GPCho 0.002 0.01 0.990 −0.31–0.31

The interaction terms of treatment (uridine or placebo) by time (baseline or follow-up) in PME, PEtn, and PCho levels were statistically significant, which suggested increased metabolite levels in the uridine group compared to the placebo group over a week of treatment. Subsequent post-hoc tests of these metabolites are presented in Table 2. PME = phosphomonoesters; PEtn = phosphoethanolamine; PCho = phosphocholine; PDE = phosphodiesters; GPEtn = glycerophosphoethanolamine; GPCho = glycerophosphocholine; CI = confidence interval.

a

Coefficient values represent percentage change of metabolite levels versus total phosphorus on the interaction term of treatment × visit, controlling for age and cerebral tissues.

b

Statistical significance (generalized estimating equation analysis, p < 0.05).